Fig. 4From: Changes of antithrombotic prescription in atrial fibrillation patients with acute coronary syndrome or percutaneous coronary intervention and the subsequent impact on long-term outcomes: a longitudinal cohort studyKaplan-Meier curve of cumulative incidence of study endpoints. The Kaplan-Meier curve of accumulative incidences of (A) primary safety endpoints and (B) secondary efficacy endpoints showed no significant differences in the two cohortsBack to article page